third quarter 2026
Filed Oct 27, 2026Zura Bio Reports Third Quarter 2026 Financial Results and Recent Corporate Updates
Zura completed enrollment above target in both ongoing Phase 2 tibulizumab studies, maintained its timelines for Q4 2026 and H1 2027 topline data, and reported cash expected to support planned operations through at least the end of 2028. The quarter also carried higher R&D and G&A expense and a larger net loss.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Research and development expenses, three months ended September 30, 2026other | $19.49M | – | – |
| General and administrative expenses, three months ended September 30, 2026other | $9.28M | – | – |
| Total operating expenses, three months ended September 30, 2026other | $28.77M | – | – |
| Loss from operations, three months ended September 30, 2026other | −$28.77M | – | – |
| Interest income, three months ended September 30, 2026other | −$1.76M | – | – |
| Other expense (income), net, three months ended September 30, 2026other | $32K | – | – |
| Total other (income), net, three months ended September 30, 2026other | −$1.73M | – | – |
| Loss before income taxes, three months ended September 30, 2026other | −$27.05M | – | – |
| Income tax benefit, three months ended September 30, 2026other | −$1.22M | – | – |
| Net loss, three months ended September 30, 2026other | −$25.82M | – | – |
| Accretion of redeemable noncontrolling interest to redemption value, three months ended September 30, 2026other | — | – | – |
| Adjustment of redeemable noncontrolling interest, three months ended September 30, 2026other | — | – | – |
| Net loss attributable to Class A Ordinary Shareholders of Zura, three months ended September 30, 2026other | −$25.82M | – | – |
| Net loss per share attributable to Class A Ordinary Shareholders of Zura, basic and diluted, three months ended September 30, 2026other | $ (0.20) | – | – |
| Weighted-average Class A Ordinary Shares used in computing net loss per share attributable to Class A Ordinary Shareholders of Zura, basic and diluted, three months ended September 30, 2026other | 127,712,533 | – | – |
| Research and development expenses, nine months ended September 30, 2026other | $54.94M | – | – |
| General and administrative expenses, nine months ended September 30, 2026other | $28.65M | – | – |
| Total operating expenses, nine months ended September 30, 2026other | $83.59M | – | – |
| Loss from operations, nine months ended September 30, 2026other | −$83.59M | – | – |
| Interest income, nine months ended September 30, 2026other | −$5.00M | – | – |
| Other expense (income), net, nine months ended September 30, 2026other | −$941K | – | – |
| Total other (income), net, nine months ended September 30, 2026other | −$5.94M | – | – |
| Loss before income taxes, nine months ended September 30, 2026other | −$77.65M | – | – |
| Income tax benefit, nine months ended September 30, 2026other | −$1.30M | – | – |
| Net loss, nine months ended September 30, 2026other | −$76.35M | – | – |
| Net loss attributable to Class A Ordinary Shareholders of Zura, nine months ended September 30, 2026other | −$76.35M | – | – |
| Net loss per share attributable to Class A Ordinary Shareholders of Zura, basic and diluted, nine months ended September 30, 2026other | $ (0.62) | – | – |
| Weighted-average Class A Ordinary Shares used in computing net loss per share attributable to Class A Ordinary Shareholders of Zura, basic and diluted, nine months ended September 30, 2026other | 122,303,170 | – | – |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
Q4 2026, H1 2027 and by year-end 2026 outlook
- NoteTibuSHIELD topline data in hidradenitis suppurativa remains on track for the fourth quarter of 2026.
- NoteTibuSURE topline data in systemic sclerosis remains on track for the first half of 2027.
- NoteNEXUS-PMR remains on track to initiate by year-end 2026.
- NoteZura expects that its existing cash and cash equivalents are sufficient to support planned operations through at least the end of 2028.
What drove it
- R&D expenses increased primarily due to the continued execution of Zura’s Phase 2 tibulizumab clinical programs and start-up activities for NEXUS-PMR.
- G&A expenses increased primarily due to higher professional fees.
- TibuSHIELD completed enrollment in June 2026 with 247 participants, exceeding its target.
- TibuSURE completed enrollment in July 2026 with 91 participants, exceeding its target.
- NEXUS-PMR has been cleared by the FDA to proceed under an Investigational New Drug application.
Concerns
- Zura reported a net loss of $25.8 million for the third quarter of 2026.
- Tibulizumab is an investigational compound and has not been approved for marketing by the FDA or any other regulatory authority.
- The filing reported no revenue, gross profit, gross margin, operating cash flow or free cash flow.
- Torudokimab and crebankitug remain under evaluation for potential development approaches.
What to watch
- TibuSHIELD topline data in hidradenitis suppurativa in the fourth quarter of 2026, including percent change from baseline in total abscess and inflammatory nodule count at Week 16 and the proportion of participants achieving HiSCR50 or HiSCR75.
- Initiation of the NEXUS-PMR Phase 2 study by year-end 2026.
- TibuSURE topline data in systemic sclerosis in the first half of 2027, including change from baseline in modified Rodnan Skin Score at Week 24 and measures of lung involvement.
- Continued spending on Phase 2 tibulizumab programs and the stated cash runway through at least the end of 2028.
Balance sheet and cash flow
- Cash and cash equivalents: $187.7 million as of September 30, 2026.
- Cash and cash equivalents: $ 187,652 as of September 30, 2026; $ 109,407 as of December 31, 2025. (In thousands)
- Prepaid expenses and other current assets: 3,940 as of September 30, 2026; 2,903 as of December 31, 2025. (In thousands)
- Total current assets: 191,592 as of September 30, 2026; 112,310 as of December 31, 2025. (In thousands)
- Property and equipment, net: 153 as of September 30, 2026; 126 as of December 31, 2025. (In thousands)
- Other assets: 2,884 as of September 30, 2026; 1,512 as of December 31, 2025. (In thousands)
- Total assets: $ 194,629 as of September 30, 2026; $ 113,948 as of December 31, 2025. (In thousands)
- Accounts payable and accrued expenses: $ 16,969 as of September 30, 2026; $ 12,410 as of December 31, 2025. (In thousands)
- Total current liabilities: 16,969 as of September 30, 2026; 12,410 as of December 31, 2025. (In thousands)
- Total liabilities: 16,969 as of September 30, 2026; 12,410 as of December 31, 2025. (In thousands)
- Additional paid-in capital: 478,549 as of September 30, 2026; 326,078 as of December 31, 2025. (In thousands)
- Accumulated deficit: (300,899) as of September 30, 2026; (224,547) as of December 31, 2025. (In thousands)
- Total shareholders’ equity: 177,660 as of September 30, 2026; 101,538 as of December 31, 2025. (In thousands)
- Total liabilities and shareholders’ equity: $ 194,629 as of September 30, 2026; $ 113,948 as of December 31, 2025. (In thousands)
- No operating cash flow, free cash flow or debt balance was reported in the filing.
Analysis
Zura’s third-quarter update was centered on clinical execution rather than commercial performance. Both ongoing Phase 2 tibulizumab studies are fully enrolled, with TibuSHIELD in hidradenitis suppurativa completing enrollment in June 2026 with 247 participants and TibuSURE in systemic sclerosis completing enrollment in July 2026 with 91 participants. Both enrollment totals exceeded target. The company maintained expected TibuSHIELD topline data in the fourth quarter of 2026 and TibuSURE topline data in the first half of 2027.
Operating spending rose as the tibulizumab development program advanced. R&D expense was $19.5 million for the third quarter of 2026 versus $11.9 million for the same period in 2025, driven primarily by execution of the Phase 2 programs and NEXUS-PMR start-up activities. G&A expense was $9.3 million versus $7.6 million, primarily due to higher professional fees. Total operating expenses were $28.8 million, and loss from operations was $28.8 million for the quarter.
The company reported net loss of $25.8 million, or $0.20 per share, compared with net loss of $18.0 million, or $0.21 per share, in the same period in 2025. For the nine months ended September 30, 2026, net loss was $76.4 million and R&D expense was $54.9 million. The filing did not report revenue, gross profit, gross margin, operating cash flow, or free cash flow, consistent with Zura’s clinical-stage profile.
Liquidity is the central financial support for the near-term pipeline catalysts. Cash and cash equivalents were $187.7 million as of September 30, 2026, and Zura stated that existing cash and cash equivalents are sufficient to support planned operations through at least the end of 2028. The balance sheet also showed additional paid-in capital of 478,549 and accumulated deficit of (300,899), each in thousands, as of September 30, 2026.
Near-term attention will be on the TibuSHIELD readout later in the fourth quarter of 2026, NEXUS-PMR initiation by year-end 2026, and the TibuSURE readout in the first half of 2027. TibuSHIELD will report percent change from baseline in total abscess and inflammatory nodule count at Week 16 and HiSCR50 or HiSCR75 response proportions. TibuSURE will report change from baseline in modified Rodnan Skin Score at Week 24 and measures of lung involvement.
Management, verbatim
Our team continues to execute efficiently on our development plan for tibulizumab, and we are excited as we enter this data-rich period for the company. We are on track to report topline results from our TibuSHIELD study in HS later this quarter, followed by topline results from our TibuSURE study in SSc in the first half of 2027.
Sandeep Kulkarni, M.D., co-founder and Chief Executive Officer of Zura
Not in the filing
stated, not guessed- Revenue
- Revenue prior-year comparison
- Revenue growth
- Segment revenue and segment comparisons
- Gross profit
- Gross margin
- Operating cash flow
- Free cash flow
- Debt balance
- Capital returns, including share repurchases and dividends
- Non-GAAP financial metrics
- Prior-quarter comparisons
- Prior outlook for comparison
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.